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SHORT REPORT
Visual field loss associated with vigabatrin:
pathological correlations
J Ravindran, P Blumbergs, J Crompton, G Pietris, H Waddy
Abstract
Pathological changes are reported in the
anterior visual pathways of a 41 year old
man with complex partial seizures treated
with vigabatrin who developed bilateral
visual field constriction. There was pe-
ripheral retinal atrophy with loss of
ganglion cells and loss of nerve fibres in
the optic nerves, chiasm, and tracts. No
evidence of intramyelinic oedema was
seen. These findings suggest that the
primary site of injury lies within the gan-
glion cells in the retina. The degree of
atrophy seen would suggest that the visual
field loss is irreversible.
(J Neurol Neurosurg Psychiatry 2001;70:787–789)
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Vigabatrin, an analogue of ã-aminobutyric acid
(GABA), irreversibly inhibits GABA transami-
nase with resultant increased concentrations of
GABA in the brain and has proved eYcacy in
the treatment of partial seizures and infantile
spasms.1 After the first report of visual field
constriction secondary to vigabatrin, this phe-
nomenon has become increasingly well recog-
nised, with a reported incidence varying from
40% to 52%.2–4 The underlying mechanism is
poorly understood.5
We report the pathological changes in the
anterior visual system of a 41 year old man with
complex partial seizures who presented with
visual field constriction. He had congenital
cyanotic heart disease, with a double outlet
single ventricle of the left ventricular type, for
which he received supplemental oxygen, warfa-
rin, and frusemide. Idiopathic adrenal failure
was diagnosed at the age of 38 years, managed
with 15 mg cortisone acetate daily. At the age
of 33 years, he presented with complex partial
seizures secondary to a streptococcal cerebral
abscess in the right parieto-occipital lobe. He
underwent stereotactic drainage and prolonged
antibiotic treatment. Brain CT 6 months later
confirmed complete resolution of the abscess.
Initial treatment of complex partial seizures
comprised 2 g/day clonazepam and 400
mg/day phenytoin. Phenytoin was substituted
with 1400 mg/day sodium valproate 4 years
later, which continued to the time of his death.
Two and a half years later vigabatrin was
started (increasing from 2 g/day to 6 g/day over
4 months) and clonazepam was stopped. Viga-
batrin was continued at 6 g/day for 5 months
followed by 5 g/day for 12 months. Over the
next 7 months, until the time of death, the dose
was maintained at 3 g/day. He received gabap-
entin (900 mg/day) for 2 months, 8 months
before his death.
Four months before his death, he noted
visual diYculties and automated visual field
testing (Octopus 1–2–3 Seven-in-One pro-
gramme) showed constricted visual fields. Two
months before his death, he noted an inability
to see houses along the street while walking
along the footpath. One month before his
death, automated visual field testing (Hum-
phrey Field Analyser Program 30–2 and 24–2)
showed bilateral concentric constriction of
visual fields, especially the nasal fields (fig 1 A,
B). The optic discs looked healthy. Vigabatrin
was stopped abruptly. Subsequently he had
complex partial seizures and cardiopulmonary
arrest with electromechanical disassociation
and died.
At postmortem the eyes, intraorbital and
intracranial optic nerves, and brain were
removed for neuropathological examination.
Routine histological assessment of the retinas
(haematoxylin and eosin stained paraYn sec-
tions of formalin fixed tissue) showed severe
atrophy of the peripheral retinas (nasal and
temporal) and less severe involvement of the
maculae. The peripheral retinas showed severe
(almost complete) loss of ganglion cells (layer
8) and partial loss of nuclei from the inner
nuclear layer 6 and outer nuclear layer 4 and
atrophy of outer and inner plexiform layers 5
and 7 and nerve fibre layer 9 (fig 2 A, B). The
optic papillae were atrophic and serial step sec-
tions of the optic nerves showed severe atrophy
(a half to a third normal size) and relative pres-
ervation of the macular fibres compared with
peripheral retinal fibres (fig 2 C). The optic
chiasm was atrophic with relative preservation
of macular fibres posteriorly (little chiasma of
Traquair). The optic tracts showed relative
preservation of the central macular fibres and
loss of medial and lateral upper and lower reti-
nal fibres (fig 2 D). There was no evidence for
intramyelinic oedema, which has been de-
scribed in some animals exposed to vigabatrin.6
This would correlate with a recent report by
Cohen et al, who found no evidence for
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intramyelinic oedema in humans exposed to
vigabatrin.7
Since the first description of visual field
defects several hypotheses have been postu-
lated as to the anatomical basis of the visual
field constriction.3 5 The visual field loss in this
case, a bilateral concentric constriction is char-
acteristic of the previously reported pattern
associated with vigabatrin.8 The peripheral
retinal atrophy and relative preservation of the
macular regions correlates well with the
concentric visual field loss and relative preser-
vation of central vision. The pattern of nerve
fibre loss in the optic nerves, chiasm, and optic
tracts is consistent with the loss of peripheral
retinal ganglion cells and relative preservation
Figure 1 (A) Left eye and (B) right eye show bilateral visual field constriction with greater loss of the nasal visual fields.
Automated visual fields 1 month before death. (Humphrey field analyser central 30–2 threshold tests.)
Figure 2 Temporal right retina (A) showing retinal atrophy with loss of ganglion cells (layer 8), partial loss of nuclei from
inner nuclear layer 6 and outer nuclear layer 4 and atrophy of outer and inner plexiform (layers 5 and 7) and nerve fibre
layers (9) compared with (B) normal control tissue (haematoxylin and eosin stained paraYn sections of formalin fixed
tissue. Postmortem delay of 15 hours with consequent autolysis involving especially layer 2 of rods and cones (A and B
originally×250)). 1=Pigment cell layer; 2=layer of rods and cones; 3=outer limiting membrane; 4=outer nuclear layer;
5=outer plexiform layer; 6=inner nuclear layer; 7=inner plexiform layer; 8=ganglion cell layer; 9=nerve fibre layer. (C)
Right optic nerve showing overall atrophy (half to one third normal) with relative preservation of the macular fibres
(Masson trichrome stain originally×24). (D) Left optic tract showing loss of myelin staining in medial (upper retinal
fibres) and lateral (lower retinal fibres) regions and relative preservation of the central macular fibres.M=medial (upper
retinal fibres); L=lateral (lower retinal fibres) (Weil stain originally×12).
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of those in the macular regions.9 There was also
loss of nuclei from the outer nuclear layer 4
(rods and cones) and the inner nuclear layer 6
but further cellular subtyping including bipolar
and amacrine cells was not possible and we
cannot be certain of the primary target(s) of
injury. The degree of atrophy seen in the retina
would suggest that the visual field loss would
be irreversible.
Studies of the human retina show that some
bipolar and amacrine cells are GABA posi-
tive.10 It has been speculated that GABA is
cytotoxic to retinal cells, especially bipolar cells
when in increased concentration. It is possible
that gabapentin acts synergistically with viga-
batrin to promote high retinal concentrations
of GABA. Other GABAergic drugs have been
implicated in the aetiology of constricted visual
field defects, raising the possibility of a class
eVect.11 The toxicity of vigabatrin on these cells
may not be related to increased GABA
concentrations directly; glutamate, a metabo-
lite of GABA, may be the mediator of cell
damage.
Electroretinogram (ERG) studies of visual
field loss associated with vigabatrin have
disclosed an abnormality of the b wave, which
is generated from the inner retina (cone
system). Oscillatory potential responses were
also lost suggestive of amacrine cell dysfunc-
tion.12 13 The pathological changes described in
this case may explain the discrepancy in the
ERG findings as some degree of atrophy of the
cone system was seen. However the predomi-
nant loss seemed to be in the ganglion cell
layer. Miller et al noted optic nerve atrophy in
some patients and changes in the visual evoked
potentials in other patients exposed to viga-
batrin.13 This finding raises the possibility of a
diVerential eVect on areas of the retina, with
some patients experiencing greater loss in the
ganglion cell layer whereas in others, the dam-
age occurs in other parts of the retina.
Concomitant use of sodium valproate has
been implicated in potentiating the adverse
eVects of vigabatrin therapy on visual fields.14
However, this finding remains controversial.15
The patient reported had received long term
sodium valproate therapy, which may have
placed him at further risk of developing
constricted visual fields. The dose of vigabatrin
prescribed was in excess of the recommended
maximum (4 g/day), which could also be a
contributory factor. Review of the literature has
not shown any reports of concentric visual field
constriction as a complication of cyanotic heart
disease. Cortical ischaemic events would not
lead to atrophy of ganglion cells in the retina or
of the optic nerves or optic tracts.
More detailed study of the eVects of
sustained doses of GABAergic agents on the
retina may help elucidate the pathophysiologi-
cal mechanisms of the visual field defect.
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